LB Pharmaceuticals Inc Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LBRX research report →
About the company
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
- CEO
- Heather D. Turner
- IPO
- 2025
- Employees
- 16
- HQ
- New York, NY, US
Price Chart
- Market Cap
- $958.66M
- P/E
- -1.56
- P/S
- 0.00
- P/B
- 2.49
- EV/EBITDA
- -16.43
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17.68%
- ROIC
- -12.23%
- Revenue
- $0 · 0.00%
- Net Income
- $-25,205,000 · 60.06%
- EPS
- $-1.00 · 94.39%
- Op Income
- $-30,404,000
- FCF YoY
- 34.49%
- 52W High
- $34.00
- 52W Low
- $13.36
- 50D MA
- $30.08
- 200D MA
- $22.91
- Beta
- 0.56
- Avg Volume
- 264.33K
Get TickerSpark's AI analysis on LBRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LBRX coverage
Recent articles, reports, and earnings notes.
No research on LBRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LBRX report →Similar companies
Peers in the same neighborhood.